Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071794 | 1.00 | FFAR4 (0.33) | FFAR4RXRAKMT2ASSTR5RARA | |
| SCHEMBL6071791 | 1.00 | FFAR4 (0.33) | FFAR4RXRAKMT2ASSTR5RARA | |
| Hydrochloric Acid SCHEMBL5784450 | 0.89 | SSTR5 (0.39) | RXRASSTR5RXRB | |
| SCHEMBL5786437 | 0.87 | SSTR5 (0.40) | FFAR4KMT2ASSTR5 | |
| SCHEMBL5783270 | 0.86 | MAPT (0.37) | FFAR4KMT2ASSTR5CREBBP | |
| SCHEMBL6071980 | 0.85 | KDM4E (0.40) | FFAR4KMT2A | |
| SCHEMBL6071970 | 0.85 | KDM4E (0.40) | FFAR4KMT2A | |
| SCHEMBL6072405 | 0.85 | PLK1 (0.37) | KMT2ASSTR5CREBBP | |
| SCHEMBL6072222 | 0.85 | FFAR4 (0.32) | FFAR4KMT2A | |
| SCHEMBL6072226 | 0.85 | FFAR4 (0.32) | FFAR4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | FFAR4 272/4885RXRA 692/4885KMT2A 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.